Perfuze
Cardiovascular Devices
$48.1Mtotal raised · 3 rounds on record
$23.8Mlatest round · Venture round · Mar 2025 · 19 mo ago
$2.7Mgrants · 1 grant · CORDIS
10+team · employees, estimated range
Overview
Developing innovative catheter technology to treat acute ischemic stroke, providing superior clinical outcomes in shorter procedural times.
Funding and backers
Total raised
$48.1M
3 rounds on record
Latest round
$23.8M
Venture round · Mar 2025 · 19 mo ago
Team
11-50
employees, estimated range
Grants
$2.7M
1 grant · CORDIS
The money's age
Due for its next round
19 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 14, 2025
Raised a round Venture round $23.8M · Silicon Republic
Feb 9, 2022
Raised a round Venture round $24.3M · Silicon Republic
Aug 1, 2019
Won a grant $2.7M · CORDIS
Apr 17, 2018
Founded per the company register
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Mar 2025 | $23.8M | — | Silicon Republic |
| Venture round | Feb 2022 | $24.3M | — | Silicon Republic |
| Grant | Aug 2019 | $2.7M | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | PERFUZE LIMITED | ie_cro |
| Registered | 17 Apr 2018 |
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Puracath reduces catheter infection risks with UV tech. Streamlined disinfection process. Contact us in San Francisco, CA for details.
VitalPath is a leading medical device contract manufacturer 100% focused on complex catheter design, rapid prototyping, and full-scale ISO…
Procyrion Aortix™ is a catheter-deployed circulatory assist device for the millions of heart failure patients who are too sick for…
ACES® from Pleural Dynamics is the first FDA-cleared implant designed for recurrent pleural effusions. Continuous relief without external…
Ablative Solutions, Inc. is investigating alcohol-mediated renal denervation delivered using the Peregrine System™ Infusion Catheter to…
Accelerating the development of life-changing technologies to bring more care to more patients suffering from stroke and other devastating…
Visa sponsorship
1
Employment permits in 12 months
0
Open roles in Ireland
In the register as Perfuze Limited
Other sponsors in the same field
Medtronic 
Boston Scientific 
Teleflex 
Edwards Lifesciences
Alert me
DETE · latest filing Jan 31, 2026 · Visa details by country
News
Perfuze: New In-Vitro Study Finds Millipede88 with Corrugated Technology Outperformed Cyclic and Conventional Aspiration
Millipede88 achieved the highest first pass effect and revascularization rates, with the lowest distal embolization, across both MCA and ICA occlusions.Perfuze, a medical device company advancing stroke
Read more
Report
Perfuze Announces Final MARRS Results: Strong Reperfusion and First-Pass Performance in Pivotal Stroke Trial
GALWAY, Ireland, August 31, 2026--Perfuze, a medical device company advancing stroke treatment through next-generation catheter technology, today announced publication of the final results of the MARRS pivotal study in the Journal of Neurointerventional S
Read more
Report
Perfuze Announces Final MARRS Results: Strong Reperfusion and First-Pass Performance in Pivotal Stroke Trial
Read more
Report
Perfuze Presents Preliminary Results from MARRS Pivotal Trial at SNIS, Highlighting Millipede88 Performance in Acute Ischemic Stroke
GALWAY, Ireland, July 16, 2025--Perfuze, a medical device company developing catheter technology for interventional stroke care, today announced positive preliminary results from its pivotal IDE clinical trial, MARRS (Millipede Aspiration for Revasculariz
Read more
Report
Perfuze Announces Completion of Enrollment in Pivotal US Clinical Study and Appointment of Joe Rotger as Executive Vice President of Sales
Read more
Report
Perfuze: €22 Million Raised And Clearance Received For Zipline Access Catheters
Perfuze, a leading medical device company dedicated to advancing stroke treatment, has received FDA 510(k) clearance for its Zipline Access Catheters. This milestone strengthens Perfuze's growing portfolio of innovative neurovascular devices, enabling phy
Read more
Report
Galway's Perfuze raises €22m, gets FDA clearance for catheter
Medtech Perfuze has raised €22m. With the infusion, the company will release its catheters to select stroke centres in the US.
Read more
Report
Perfuze Announces FDA Clearances for Novel Neurovascular Aspiration and Access Catheters for Stroke Treatment
Read more
Report
Irish medtech Perfuze raises €22.5m for stroke treatment device
Perfuze is developing catheter-based technology to remove blood clots from the brain in one pass to treat acute ischemic stroke.
Read more
Report
Perfuze Receives Breakthrough Device Designation Status from U.S. Food and Drug Administration (FDA) for Millipede CIS (Clot Ingestion System)
Perfuze is developing novel catheter-based technology for treating acute ischemic stroke Receives Breakthrough Device Designation Status from the FDA Perfuze, a medical device company
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Galway
Ireland
HQ
Privacy Policy
10-50 est. staff